Cibus (CBUS) Stock Price, News & Analysis

Company Overview

Cibus, Inc. is an agricultural biotechnology company that develops gene-edited traits for crops. Its technology is designed to make targeted changes to plant genetics without introducing foreign DNA, with the goal of improving crop performance, productivity and sustainability.

The company’s proprietary Rapid Trait Development System (RTDS) platform is used to develop traits for the global seed industry. Cibus has focused on crops including canola, soybean and rice, pursuing applications such as improved disease resistance, herbicide tolerance, reduced pod shatter and other traits intended to support farmers and seed companies.

Founded in 2001, Cibus became a publicly traded company following its 2023 merger with Calyxt, Inc. The company is headquartered in San Diego, California, and works with agricultural and seed-industry partners to advance and commercialize gene-edited crop traits. Cibus is led by co-founder Peter Beetham, Ph.D., who serves as president and chief executive officer.

Key Stats

• Today's Range: $1.56 to $1.67
• 50-Day Range: $1.49 to $2.39
• 52-Week Range: $1.09 to $4.19
• Volume: 139,149 shs
• Average Volume: 99,607 shs
• Market Capitalization: $123.05 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.00
• Consensus Rating: Hold

Cibus Stock Analysis - MarketRank™

Cibus scored higher than 31% of companies evaluated by MarketBeat, and ranked 786th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Cibus has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.

Upside Potential

Cibus has a consensus price target of $9.00, representing about 459.0% upside from its current price of $1.61.

Amount of Analyst Coverage

Cibus has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cibus are expected to grow in the coming year, from ($1.13) to ($1.07) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cibus is -0.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cibus is -0.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cibus has a P/B Ratio of 4.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.48% of the float of Cibus has been sold short.

Short Interest Ratio / Days to Cover

Cibus has a short interest ratio ("days to cover") of 32.67, which indicates bearish sentiment.

Change versus previous month

Short interest in Cibus has recently increased by 2.47%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cibus does not currently pay a dividend.

Dividend Growth

Cibus does not have a long track record of dividend growth.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: N/A

News Sentiment

Cibus has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Cibus this week, compared to 3 articles on an average week.

Search Interest

2 people have searched for CBUS on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cibus insiders have not sold or bought any company stock.

Percentage Held by Insiders

29.91% of the stock of Cibus is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

33.81% of the stock of Cibus is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 9/20/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:CBUS
• Previous Symbol: NASDAQ:CBUS
• CIK: 1705843
• Web: www.cibus.com
• Phone: (858) 450-0008
• Fax: N/A
• Employees: 118
• Year Founded: 2001

Price Target and Rating

• Average Price Target for Cibus: $9.00
• High Price Target: $15.00
• Low Price Target: $3.00
• Potential Upside/Downside: +459.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.65)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$127.08 million
• Net Margins: -2,258.89%
• Pretax Margin: -2,291.35%
• Return on Equity: -287.03%
• Return on Assets: -27.99%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.62
• Quick Ratio: 1.62

Sales & Book Value

• Annual Sales: $3.64 million
• Price / Sales: 33.81
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.40 per share
• Price / Book: 4.03

Miscellaneous

• Outstanding Shares: 76,430,000
• Free Float: 53,569,000
• Market Cap: $123.05 million
• Optionable: Optionable
• Beta: 1.59